In particular, one of the novel tribodies, called 53L10, a tri-specific T cell engager targeting 5T4, CD3 and PD-L1 IC, showed the most promising anti-tumor efficacy in vitro and in vivo. This evidence concerns the gene TPBG and neoplasm.